Spotlight Medical

1 known investors

Spotlight Medical develops AI-enabled prognostic assays for cancer risk assessment, starting with myStage Dx, a test for early-stage ER+/HER2– breast cancer that helps clinicians identify low-risk patients within high-risk clinical groups. The assay analyzes routine pathology slides using machine learning to generate personalized relapse risk scores.